GREENWICH LIFESCIENCES
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.
GREENWICH LIFESCIENCES
Industry:
Biopharma Biotechnology Life Science
Founded:
2006-01-01
Address:
Stafford, Texas, United States
Country:
United States
Website Url:
http://www.greenwichlifesciences.com
Total Employee:
1+
Status:
Active
Contact:
(832) 819-3232
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
BioAdvance
BioAdvance is a Pennsylvania-based venture capital firm that provides funding to life sciences startups.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Recognify Life Sciences
Recognify Life Sciences is an entity developing a treatment for Cognitive Impairment associated with Schizophrenia ("CIAS").
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.greenwichlifesciences.com Semrush global rank: 3.54 M Semrush visits lastest month: 4.15 K
- Host name: 192-254-225-12.unifiedlayer.com
- IP address: 192.254.225.12
- Location: Houston United States
- Latitude: 29.8284
- Longitude: -95.4696
- Metro Code: 618
- Timezone: America/Chicago
- Postal: 77092
More informations about "Greenwich LifeSciences"
About | Greenwich LifeSciences, Inc. (GLSI) | GP2
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is a clinical-stage public biopharmaceutical company based in the Houston, TX area that is developing GP2, a novel peptide …See details»
Company Information | Greenwich LifeSciences, Inc.
Company Greenwich LifeSciences, Inc. 3992 Bluebonnet Drive Building 14 Stafford, TX 77477 T: 832-819-3232See details»
Investors & Media | Greenwich LifeSciences, Inc. (GLSI) …
Company Profile. Business Description: Greenwich LifeSciences (the “Company”) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who …See details»
Leadership | Greenwich LifeSciences, Inc. (GLSI) | GP2
Dr. Thompson has over 30 years of experience in pharmaceutical and device product development. She is a co-founder, clinical advisor, and former Chief Operating Officer of …See details»
Greenwich LifeSciences - Crunchbase Company Profile …
Contact Email [email protected] Phone Number (832) 819-3232 Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of an immunotherapy to prevent breast cancer …See details»
Corporate Governance | Greenwich LifeSciences, Inc.
Snehal S. Patel Chief Executive Officer. Over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare industry.See details»
Greenwich LifeSciences Provides Updated Corporate Presentation …
Nov 9, 2021 Contacts. Company Contact Snehal Patel Investor Relations (832) 819-3232 [email protected] Investor & Public Relations Contact for Greenwich …See details»
Greenwich LifeSciences Announces Commencement of the First …
Dec 6, 2021 Contacts. Company Contact Snehal Patel Investor Relations Office: (832) 819-3232 Email: [email protected] Investor & Public Relations Contact for Greenwich …See details»
Contact | Greenwich LifeSciences, Inc. (GLSI) | GP2
About. management team; board of directors; technology. our gp2 cancer immunotherapy product; cancer and immunotherapy background; clinical trials. completed phase iib clinical trialSee details»
Greenwich LifeSciences Provides Updates on Recent and …
Sep 9, 2021 Contacts. Company Contact Snehal Patel Investor Relations (832) 819-3232 [email protected] Investor & Public Relations Contact for Greenwich …See details»
Greenwich LifeSciences Provides Update on Upcoming Phase III …
Feb 1, 2022 - Contract Research Organization (CRO) has been contracted for study start-up, project management, data management, and clinical data monitoring ... Email: …See details»
Technology | Greenwich LifeSciences, Inc. (GLSI) | GP2
GP2 immunotherapy trains a patient’s T cells to recognize and destroy HER2/neu-expressing cancer cells as they recur.See details»
Greenwich LifeSciences Provides Updates on Upcoming
Mar 3, 2022 The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer and has more than 48,000 members residing in 127 …See details»
Greenwich Lifesciences Inc (GLSI) Stock Price & News - Google
Get the latest Greenwich Lifesciences Inc (GLSI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.See details»
Clinical Trials | Greenwich LifeSciences, Inc. (GLSI) | GP2
The current trial is a Phase III clinical trial registered with the name, Flamingo-01, and the identifier, NCT05232916. The cGMP manufacturing of GP2 for the trial is complete, Greenwich …See details»
Greenwich LifeSciences Presents Phase IIb Data, Published at …
Apr 19, 2022 The AACR is the first and largest cancer research organization dedicated to accelerating the conquest of cancer and has more than 48,000 members residing in 127 …See details»
Flamingo-01 Phase III Clinical Trial - Greenwich LifeSciences, Inc.
[email protected]. Flamingo-01 Trial Design. The Flamingo-01 Phase III trial is a prospective, randomized, double-blinded, multi-center study. The patient population is …See details»
Greenwich LifeSciences Publishes Additional Positive Safety Data …
[email protected]. Investor & Public Relations Contact for Greenwich LifeSciences Dave Gentry RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447) Cell: (407) 491 …See details»
Greenwich LifeSciences Partners with GIM in Italy
3 days ago Related questions and participation interest can be emailed to: [email protected]. About Breast Cancer and HER2/neu Positivity. One in eight …See details»